KRAS and adenocarcinoma: Indeed, the chemo-immunotherapy was authorized for prescription as early as October 2019 for adenocarcinoma and April 2020 for squamous-cell carcinoma, while certain targeted therapies were granted early access (sotorasib for KRas G12C mutations in the second-line since June 2021) or were routinely prescribed (osimertinib as first-line therapy since October 2020).